Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Schering-Plough's Vancenase AQ

Executive Summary

Schering-Plough's Vancenase AQ: Switch to OTC status for Schering's beclomethasone dipropionate and Fisons' Nasalcrom (cromolyn sodium) nasal sprays (to be marketed by McNeil) will be considered at a joint meeting of FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees on Oct. 11. Both sprays would be indicated for the OTC treatment of seasonal allergic rhinitis at the current Rx dosage.... Chiral ibuprofen: On Oct. 10, FDA's Nonprescription Drugs and Arthritis Advisory Committees will consider an application for dexibuprofen to be marketed by Bayer. The application apparently is seeking approval straight to OTC status...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel